Immunoprecise Antibodies Ltd expected to post a loss of 13 cents a share - Earnings Preview

Mindwalk Holdings

12/12/2023 13:33

* Immunoprecise Antibodies Ltd  IPA.OQ   IPA.O  is expected
to show a rise in quarterly revenue when it reports  results on
December 14 for the period ending July 31 2023
    * The Victoria British Columbia-based  company is expected
to
report a 12.9% increase in revenue to C$5.853 million from
C$5.18 million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Immunoprecise Antibodies
Ltd
is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
Immunoprecise
Antibodies Ltd is $8.00​, above​ its last closing price
of $1.14. ​​​

This summary was machine generated December 12 at 13:33 GMT. 
All figures in Canadian dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)